Wells Fargo & Co. (WFC, Financial), United Parcel Service Inc. (UPS, Financial), Gilead Sciences Inc. (GILD, Financial) and Bristol-Myers Squibb Company (BMY, Financial) have declined to their three-year lows.
Wells Fargo & Co. (WFC, Financial) declined to $44.37
The prices of Wells Fargo & Co. (WFC, Financial) shares have declined to $44.37 on May 31, which is only 3.0% above the 3-year low of $43.02.
Wells Fargo & Co. is an American international banking and financial services holding company. The bank is the world’s second largest bank by market capitalization and the third largest bank in the United States by assets. The company is the second largest bank in deposits, home mortgage servicing, and debit cards.
Wells Fargo & Co. has a market cap of $199.41 billion; its shares were traded around $44.37 with a P/E ratio of 9.83 and P/S ratio of 2.48. The trailing 12-month dividend yield of Wells Fargo & Co. stocks is 4.00%. The forward dividend yield of Wells Fargo & Co. stocks is 4.00%.
On May 29 Wells Fargo & Co. announced that Charles H. Noski has been elected to the company’s Board of Directors, effective June 1. Noski will serve on the board’s Audit and Examination Committee. Noski has served in numerous senior leadership roles, including as vice chairman of Bank of America Corporation, CFO and a director of Northrop Grumman Corporation, and CFO and vice chairman of AT&T Corporation.
United Parcel Service Inc. (UPS, Financial) declined to $92.92
The prices of United Parcel Service Inc. (UPS, Financial) shares have declined to $92.92 on May 31, which is only 3.3% above the 3-year low of $89.89.
United Parcel Service Inc. is an American international delivery company and a provider of supply chain management solutions. The company is also the largest package delivery company in the world, delivering more than 15 million packages per day to 7.9 million customers in more than 220 countries and territories around the world.
United Parcel Service Inc. has a market cap of $79.98 billion; its shares were traded around $92.92 with a P/E ratio of 17.74 and P/S ratio of 1.14. The trailing 12-month dividend yield of United Parcel Service Inc. stocks is 4.02%. The forward dividend yield of United Parcel Service Inc. stocks is 4.01%. United Parcel Service Inc. had an annual average earnings growth of 6.10% over the past 10 years.
On May 22 United Parcel Service Inc. announced an agreement with Clean Energy Fuels Corp. to purchase 170 million gallon equivalents of renewable natural gas through 2026. This is the largest commitment for use of renewable natural gas to date by any company in the United States, supporting the company’s efforts to reduce the absolute greenhouse gas emissions of its ground fleet.
Gilead Sciences Inc. (GILD, Financial) declined to $62.25
The prices of Gilead Sciences Inc. (GILD, Financial) shares have declined to $62.25 on May 31, which is only 3.1% above the 3-year low of $60.32.
Gilead Sciences Inc. is an American international pharmaceutical and biotechnology company that develops and commercializes therapeutics. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza. Some of the products that the company developed include AmBisome, Atripla, Cayston, Emtriva, and Flolan.
Gilead Sciences Inc. has a market cap of $79.15 billion; its shares were traded around $62.25 with a P/E ratio of 13.75 and P/S ratio of 3.62. The trailing 12-month dividend yield of Gilead Sciences Inc. stocks is 3.75%. The forward dividend yield of Gilead Sciences Inc. stocks is 3.98%. Gilead Sciences Inc. had an annual average earnings growth of 26.10% over the past 10 years.
On April 12 Gilead Sciences Inc. announced that it intends to collaborate with Novo Nordisk A/S on a clinical trial that combines compounds from their respective pipelines in nonalcoholic steatohepatitis. The intended clinical trial will be a proof of concept study combing Novo Nordisk’s semaglutide and Gilead’s cilofexor for the treatment of patients with NASH.
Bristol-Myers Squibb Company (BMY, Financial) declined to $45.37
The prices of Bristol-Myers Squibb Company (BMY, Financial) shares have declined to $45.37 on May 31, which is only 2.4% above the 3-year low of $44.30.
Bristol-Myers Squibb Company is an American international pharmaceutical company that manufactures prescription pharmaceuticals in various therapeutic areas including cancer, cardiovascular diseases, diabetes, hepatitis, and HIV.
Bristol-Myers Squibb Company has a market cap of $74.21 billion; its shares were traded around $45.37 with a P/E ratio of 14.33 and P/S ratio of 3.18. The trailing 12-month dividend yield of Bristol-Myers Squibb Company stocks is 3.56%. The forward dividend yield of Bristol-Myers Squibb Company stocks is 3.57%. Bristol-Myers Squibb Company had an annual average earnings growth of 18.40% over the past 5 years.
On May 8 Bristol-Myers Squibb Company announced that it has priced its previously announced private offering of senior unsecured notes in a combined aggregate principal amount of $19 billion. The notes were issued in nine tranches and the closing of the offering occurred on May 16.
Disclosure: I do not own stock in any of the companies mentioned in the article.
